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Group B Streptococcus (GBS) is a leading cause of neonatal sepsis, pneumonia and 23 
meningitis worldwide. In the majority of cases, GBS is transmitted vertically from mother 24 
to neonate, making maternal vaginal colonisation a key risk factor for neonatal disease. 25 
The fungus Candida albicans is an opportunistic pathogen of the female genitourinary 26 
tract, and the causative agent of vaginal thrush. Carriage of C. albicans has been 27 
shown to be an independent risk factor for vaginal colonisation by GBS. However, the 28 
nature of interactions between these two microbes is poorly understood. This study 29 
provides evidence of a reciprocal, synergistic interplay between GBS and C. albicans 30 
that may serve to promote their co-colonisation of the vaginal mucosa. GBS strains 31 
NEM316 (serotype III) and 515 (Ia) are shown to physically interact with C. albicans, 32 
with bacteria exhibiting tropism for candidal hyphal filaments. This interaction enhances 33 
association levels of both microbes with vaginal epithelial cell line VK2/E6E7. The ability 34 
of GBS to co-associate with C. albicans is dependent upon expression of hyphal-35 
specific adhesin Als3. In turn, expression of GBS antigen I/II family adhesins (Bsp 36 
polypeptides) facilitates this co-association and confers upon surrogate Lactococcus 37 
lactis the capacity to exhibit enhanced interactions with C. albicans on vaginal 38 
epithelium. As genitourinary tract colonisation is an essential first step in the 39 
pathogenesis of GBS and C. albicans, the co-association mechanism reported here 40 




Streptococcus agalactiae (Group B Streptococcus, GBS) is a leading cause of 43 
invasive disease (sepsis, pneumonia, meningitis) in neonates, and is responsible for life 44 
threatening infections in elderly and immune-compromised individuals (1-3). GBS is an 45 
opportunistic pathogen of the female genitourinary (GU) tract, with a carriage rate in 46 
Western countries of approximately 30% (2). The primary route of transmission to 47 
neonates is from the mother during or preceding birth, with transmission rates estimated 48 
at up to 50% (2). Of those neonates that are colonised, about 1% develop severe GBS 49 
disease, resulting in significant infant morbidity or mortality (2, 4).  50 
A variety of proteins have been identified on the surface of GBS that may promote 51 
colonisation of host mucosae. These include pili (5), alpha C protein (6), BibA (7), 52 
serine-rich repeat proteins (Srr1/2) (5, 8), FbsA (9), Lmb (10), and the recently 53 
characterised antigen I/II (AgI/II) family proteins, designated BspA-D (11, 12). Many of 54 
these surface proteins have been shown to target receptors expressed directly on the 55 
cervical or vaginal epithelia, while others bind extracellular matrix (ECM) proteins such 56 
as collagen, fibrinogen, fibronectin or laminin (5, 8-10). An additional colonisation 57 
strategy for GBS, but one that remains poorly understood, is via interactions with other 58 
members of the vaginal microbiota. It is widely accepted that a ‘healthy’ vaginal 59 
microbiota is dominated (ca. 70%) by the genus Lactobacillus, but Gram-positive 60 
bacteria (e.g. streptococci, staphylococci), Gram-negative bacteria (e.g. Escherichia 61 
coli) and yeasts (e.g. Candida albicans) are also frequently isolated (13). Of particular 62 
relevance to GBS colonisation is a growing body of evidence indicating an association 63 
with fungus C. albicans. In both developed and developing countries, vaginal carriage of 64 
4 
 
C. albicans has been shown to be an independent risk factor for vaginal colonisation by 65 
GBS (14-18).  66 
 C. albicans accounts for the fourth highest rate of systemic nosocomial infection 67 
in the US (19), and as an opportunistic pathogen of the oropharynx and female GU tract 68 
is the predominant cause of both oral and vaginal thrush. Key risk factors for C. albicans 69 
infection are immunosuppression, use of oral contraceptives, hormone therapy, 70 
antibiotics, diabetes, and pregnancy (20). A number of colonisation determinants have 71 
been implicated in promoting candidal adhesion to and invasion of mucosae. These 72 
include proteins that are expressed on the surface of both morphological forms 73 
(blastospore and hypha) of C. albicans such as Als1, Eap1, Eno1, Pra1 and Tdh1 (21-74 
25). Other major candidal adhesins, including Hwp1, Als3 and Ssa1, are exclusively 75 
expressed on the filamentous hyphae (22, 26, 27). Similarly to GBS, epithelial receptor 76 
molecules (e.g. CEACAMs, cadherins) or ECM proteins (e.g. fibronectin, laminin) have 77 
been identified as targets for these C. albicans adhesins (25, 27-29). 78 
Synergistic polymicrobial interactions have already been described for C. albicans 79 
and a number of Gram-positive bacteria. For example, oral bacterium Streptococcus 80 
gordonii produces nutrient by-products that are stimulatory to C. albicans, enhancing 81 
the length of hyphal filaments (30). In turn, S. gordonii benefits from the reduced oxygen 82 
environment generated by C. albicans metabolism (31). Physical coadhesion between 83 
these two microbes also serves to promote retention of C. albicans within the oral 84 
cavity, the molecular basis of which has been identified as recognition of C. albicans 85 
adhesin Als3 by S. gordonii AgI/II family protein SspB (32). Similar interactions have 86 
been reported for Streptococcus mutans and C. albicans, for which S. mutans 87 
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glucosyltransferase GtfB has been shown to bind mannans on the candidal cell surface, 88 
promoting robust cross-kingdom biofilm formation within the oral cavity of rats (33). In 89 
addition to niche colonisation, interkingdom interactions may modulate disease 90 
progression. Streptococcus oralis and C. albicans synergise within the oropharynx to 91 
promote breakdown of epithelial tight junctions, resulting in enhanced systemic 92 
dissemination of C. albicans (34, 35). Likewise Staphylococcus aureus has a high 93 
affinity for binding C. albicans hyphae and can ‘piggy back’ on these filamentous forms 94 
as they infiltrate host cells to gain access to deeper tissues (36). Again, staphylococcal 95 
recognition of C. albicans hyphal protein Als3 is critical for this coadhesion (37). 96 
We have recently characterised the AgI/II family polypeptide of GBS designated 97 
BspA. Alongside binding to salivary pellicle and vaginal epithelium, BspA was shown to 98 
promote coaggregation of GBS strain NEM316 with C. albicans under planktonic 99 
conditions (12). This study therefore aimed to build on these initial observations and 100 
determine in more detail the interkingdom interactions between GBS and C. albicans, 101 
and to investigate their potential to modulate the colonisation or pathogenic capabilities 102 
of these two microbes within the GU tract.  103 
  104 
RESULTS 105 
Planktonic interactions of GBS and C. albicans. The first step in exploring the 106 
interactions of GBS with C. albicans was to confirm their capacity to coaggregate under 107 
planktonic conditions. Two strains of GBS were tested that represent two of the most 108 
common capsular serotypes associated with neonatal disease: GBS strain 515, 109 
capsular serotype Ia, and strain NEM316, capsular serotype III (Table 1). C. albicans 110 
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was fluorescently-labelled with Calcofluor White, while GBS strains were labelled with 111 
FITC. Suspensions were then incubated together for 1 h before visualisation by 112 
fluorescence microscopy. Both GBS strains were able to coaggregate with C. albicans, 113 
indicating that these interactions are not restricted to a single capsular serotype (Fig. 1). 114 
Furthermore, as reported by (12), GBS strain NEM316 exhibited a tropism for C. 115 
albicans hyphae rather than blastospores. This binding pattern was also apparent with 116 
GBS strain 515, although higher levels of association were seen overall with strain 117 
NEM316 (Fig. 1). Taken together, these data confirmed that GBS can undergo 118 
planktonic interactions with C. albicans, but implied that levels of coaggregation may be 119 
strain-dependent. 120 
GBS-C. albicans interactions with vaginal epithelial cells. Since GBS and C. 121 
albicans are able to coaggregate, we hypothesised that such interactions could 122 
influence the capacity of these microbes to associate with vaginal epithelium. To this 123 
end, an in vitro assay was developed using vaginal epithelial cell (VEC) line VK2/E6E7. 124 
In the first instance, epithelial cell monolayers were exposed either to GBS alone for 1 125 
h, or to C. albicans for 1 h to initiate hyphae formation, followed by GBS for a further 1 126 
h. Numbers of associated GBS were then enumerated by viable count (CFU) from 127 
epithelial cell lysates. While GBS strain NEM316 showed higher levels of association 128 
(1.51x105 CFU/monolayer) compared to strain 515 (7.57x104 CFU/monolayer) (Fig. 2), 129 
both strains exhibited a strong affinity for the VEC monolayers. However, significantly 130 
higher numbers of bacteria were recovered for both strains in the presence of C. 131 
albicans. Numbers of GBS recovered from the epithelium were 1.9-fold higher for strain 132 
NEM316 and 2.1-fold higher for strain 515 compared to their respective monospecies 133 
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samples (Fig. 2). These augmentory effects were verified by confocal microscopy, 134 
although a slightly longer incubation period was needed (5 h) to obtain bacterial cell 135 
numbers that were of sufficient abundance to be clearly visible (Fig. 3). For 136 
monospecies samples, both GBS strains were evenly distributed across the VECs, but 137 
numbers of GBS cells were higher per field of view for strain NEM316 than 515 (Fig. 3, 138 
columns 1-2). In the presence of C. albicans, an increase in the numbers of GBS 139 
associated with the VECs was apparent for both strains (Fig. 3, columns 3-4) compared 140 
to the monospecies equivalent. This was verified by quantification of GBS biovolume 141 
(Fig. 4A). In the presence of C. albicans, GBS biovolume levels were 4.6-fold and 2.8-142 
fold higher for strains NEM316 and 515 respectively than their monospecies equivalent 143 
(Fig. 4A). Many GBS cells could be seen interacting with C. albicans hyphae, which 144 
formed extensive mats that overlaid the epithelial monolayers (see white arrows, Fig. 3). 145 
However, there was also a visible increase in the numbers of GBS interacting with the 146 
epithelium in areas that were not seemingly colonised by C. albicans (see red arrows, 147 
Fig. 3). This pattern was seen for both GBS strains. Augmentation by C. albicans of 148 
GBS association with VECs after 5 h was further supported by enumeration of GBS 149 
from recovered epithelial lysates, and more strikingly demonstrated the effects with 150 
GBS strain 515 (Fig. 4B).  151 
To investigate the potential for a reciprocal relationship between GBS and C. 152 
albicans, the effects of GBS on C. albicans association with vaginal epithelium were 153 
then explored using the same in vitro assay. For both strains tested, the presence of 154 
GBS resulted in a 4-fold elevation in the levels of C. albicans recovered from the VEC 155 
monolayers compared to C. albicans alone (Fig. 5). These data imply that a synergistic 156 
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relationship exists between C. albicans and GBS, and that each microbe can enhance 157 
association of the other with vaginal epithelium. 158 
Role of diffusible signals in GBS-C. albicans interactions. One potential 159 
mechanism for the enhanced recovery of both GBS and C. albicans when co-cultured 160 
with vaginal epithelium might be that each microbe releases some form of diffusible, 161 
chemical signal that either stimulates growth of the other or promotes its capacity to 162 
associate with VECs. To explore the first possibility, growth of GBS and C. albicans in 163 
single- or dual-species suspensions were compared. These studies were performed 164 
under similar conditions to the in vitro cell culture assay, using keratinocyte serum-free 165 
medium (K-SFM) and incubation periods of 1-2 h. No significant differences in CFU 166 
were seen for either species (Fig. 6A,B), regardless of whether grown in mono- or dual-167 
species conditions. This implied that the presence of C. albicans does not affect the 168 
overall growth rate of GBS, and vice versa.  169 
To determine if diffusible signals were modulating microbial interactions with the 170 
vaginal epithelium, GBS was incubated with VEC monolayers in K-SFM, or in spent 171 
media harvested from C. albicans grown in K-SFM for 1 h in the presence or absence of 172 
VECs. After 1 h incubation with VEC monolayers, numbers of associated GBS were 173 
enumerated by viable count from epithelial cell lysates. No significant differences were 174 
observed between numbers (CFU/monolayer) of GBS recovered across the different 175 
conditions (Fig. 7A). 176 
For the reciprocal study, C. albicans was incubated on VEC monolayers for 1 h, 177 
and then suspensions of GBS or K-SFM alone were placed in transwell inserts above 178 
the VECs. Viable counts of C. albicans were determined after a further 1 h incubation. 179 
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Again, no significant differences were seen in C. albicans association levels with VECs 180 
in the presence or absence of GBS (Fig. 7B). 181 
One final possibility explored was that GBS or C. albicans modulated the 182 
permissiveness of VECs to association with the other microbe via an active but contact-183 
dependent mechanism. This was investigated by repeating the association assays 184 
using paraformaldehyde-fixed VECs. Fixation reduced the numbers of GBS recovered 185 
from the cell lysates overall. Nonetheless, the presence of C. albicans again resulted in 186 
elevated association levels of GBS (Fig. 7C) and the reciprocal effect was seen for 187 
levels of C. albicans recovered in the presence of GBS (Fig. 7D). Taken together, these 188 
data imply that neither intermicrobial diffusible signals nor active modulation of VEC 189 
receptor profile are required for enhanced co-association of GBS or C. albicans with 190 
vaginal epithelium. 191 
Role of Bsp protein in GBS-C. albicans interactions. Oral streptococci have 192 
been shown to promote the colonisation and retention of C. albicans within the oral 193 
cavity and this is mediated, in large part, by coadhesion between the microbes (31). 194 
Having demonstrated similar coadhesion between GBS and C. albicans, the next step 195 
was to determine the molecular basis for this physical interaction and its contribution to 196 
the synergistic effects seen with vaginal epithelium. 197 
We have recently shown that AgI/II family protein BspA of GBS strain NEM316 198 
promotes coaggregation with C. albicans under planktonic conditions (12). We therefore 199 
wanted to build on this observation and determine if the Bsp adhesin family was 200 
important in GBS augmenting interactions of C. albicans with VECs. In the first instance 201 
a bspC knockout mutant was generated in GBS strain 515, which carries only a single 202 
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copy of the bspC gene (a homologue of bspA). This strain displayed only a modest (ca. 203 
15%) reduction in association with VECs when compared to parent strain 515 (Fig. 8A). 204 
However, it has been reported previously that streptococci can compensate for loss of 205 
antigen I/II family proteins by upregulation of alternative adhesins (38). To further 206 
explore the role of Bsp adhesins, inhibition studies were therefore performed using 207 
specific antisera. Anti-Bsp sera reduced association of wild-type GBS strains NEM316 208 
and 515 to VECs by 46% and 63% respectively compared to preimmune control (Fig. 209 
8B). Together these data support previous evidence that Bsp adhesins have capacity to 210 
promote GBS interactions with vaginal epithelium (12), but indicate that there are 211 
additional determinants utilised by GBS for this purpose.  212 
In the presence of C. albicans, a more significant difference was seen between 213 
parent 515 and bspC knockout strains. C. albicans significantly promoted recovery of 214 
both GBS strains from the epithelium compared to their respective monospecies 215 
samples. However, numbers of bacteria recovered were approximately 30% lower for 216 
mutant strain 515 bspC than parent 515 (Fig. 8A). These data imply that BspC plays a 217 
role in mediating GBS co-association with C. albicans. However, additional adhesins 218 
must be involved and may compensate for the lack of BspC in strain 515 bspC.  219 
Given this apparent adhesin redundancy, surrogate Lactococcus lactis strains 220 
expressing BspA or BspC were then employed in co-association assays. This allowed 221 
the functional properties associated with the individual AgI/II family proteins to be 222 
explored in greater detail. For monospecies L. lactis, once again only a modest increase 223 
was seen in numbers of bacteria recovered from VECs expressing BspA or BspC 224 
compared to the empty vector control strain (Fig. 9). However, for dual species 225 
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samples, recoveries of L. lactis strains expressing BspA or BspC were promoted by 1.8-226 
fold or 3-fold respectively by C. albicans (Fig. 9), while vector-only L. lactis controls 227 
were increased only slightly (<0.5-fold). Overall this implies that GBS AgI/II family 228 
proteins have capacity to promote GBS association with vaginal epithelium directly, but 229 
they likely play a greater role by promoting association via C. albicans. 230 
Role of Als3 protein in GBS-C. albicans interactions. A possible receptor for 231 
the Bsp proteins of GBS was candidal glycoprotein Als3, since this adhesin is hypha-232 
specific (22) and has been shown to bind the AgI/II family protein SspB of S. gordonii to 233 
mediate interkingdom interactions (32). A C. albicans strain with both alleles of the als3 234 
gene deleted (39), as well as a corresponding complemented strain (Δals3+als3), were 235 
used to determine if Als3 is involved in interactions between GBS and C. albicans. This 236 
was first investigated under planktonic conditions, and levels of coaggregation were 237 
determined semi-quantitatively according to numbers of GBS associated with individual 238 
hyphae. Both GBS strains exhibited strong interactions with C. albicans wild type 239 
SC5314 and C. albicans Δals3+als3 strains, with the majority of hyphae recorded as 240 
binding 6-20 bacteria or >20 bacteria (Fig. 10). By contrast, the majority of C. albicans 241 
Δals3 hyphae were either devoid of bacterial cells or bound only 1-5 GBS cells (Fig. 10). 242 
Thus the expression of Als3 on candidal hyphae is required to mediate strong physical 243 
interactions with GBS under planktonic conditions.  244 
These various C. albicans strains were then used to determine if Als3-mediated 245 
interactions were required to modulate GBS association with VECs. Interestingly, 246 
numbers of C. albicans Δals3 associated with VECs were not significantly different from 247 
those recovered for wild type SC5314 or C. albicans Δals3+als3 strains. This was 248 
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contrary to observations made by others (39) in studies with oral epithelium and implies 249 
that Als3 may exhibit tissue-specific tropism. Unlike the phenomenon observed with C. 250 
albicans wild type, there was no enhanced association of GBS with C. albicans Δals3 in 251 
the presence of VECs, and numbers of GBS recovered were comparable to those from 252 
monospecies samples (Fig. 11). By contrast, complementation of Δals3 in strain C. 253 
albicans Δals3+als3 restored the capacity for C. albicans to significantly promote GBS 254 
association with vaginal epithelium relative to GBS monospecies samples (Fig. 11). 255 
A similar scenario was seen for the reciprocal studies to determine the role of Als3 256 
in GBS modulation of C. albicans interactions with VECs. Numbers of C. albicans Δals3 257 
cells recovered from epithelial monolayers were comparable for monospecies samples 258 
and dual-species samples incorporating either of the two GBS strains (Fig. 12). By 259 
contrast, both of the GBS strains enhanced the recovery of C. albicans Δals3+als3 by 260 
2.5-fold (Fig. 12) relative to the monospecies control. These latter effects were similar to 261 
those seen previously with C. albicans wild type SC5314 (Fig. 5). Thus, Als3 expression 262 
by C. albicans is required for both GBS and C. albicans to modulate co-association with 263 
vaginal epithelium. 264 
Finally, studies were performed to investigate if Bsp polypeptides of GBS can bind 265 
directly to Als3 of C. albicans. Again, to avoid potential issues with adhesin redundancy, 266 
surrogate expression strains were utilised. A strain of Saccharomyces cerevisiae had 267 
previously been generated that expresses the small allele of C. albicans Als3 on its cell 268 
surface (40). This S. cerevisiae (Als3+) strain was fluorescently-labelled with FITC, 269 
while L. lactis strains expressing BspA, BspC or empty vector control were labelled with 270 
TRITC. Suspensions were then incubated together for 1 h before visualisation by 271 
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fluorescence microscopy. No interactions were seen between S. cerevisiae (Als3+) and 272 
L. lactis control (Fig. 13A). By contrast, coggregation could clearly be seen with S. 273 
cerevisiae (Als3+) and L. lactis strains expressing either BspA (Fig. 13B) or BspC (Fig. 274 
13C). Thus GBS polypeptides BspA and BspC are direct binding partners for Als3 of C. 275 
albicans.  276 
  277 
DISCUSSION 278 
Intermicrobial interactions occur at most sites of colonisation within the human 279 
body and, according to the National Institutes of Health, biofilms underpin approximately 280 
80% of infections (41). In some instances, these interactions have antagonistic 281 
outcomes, such as those between C. albicans and Pseudomonas aeruginosa. Other 282 
partnerships are seemingly synergistic in nature, such as the interactions between C. 283 
albicans and S. gordonii, S. oralis, S. mutans or Staph. aureus (32, 35, 37, 42). Several 284 
studies have reported co-occurrence of GBS and C. albicans within the GU tract (14-285 
18), and we recently provided evidence for coaggregation between these two microbes 286 
(12). The aims of this study were therefore to further define the interkingdom 287 
interactions of these two microbes and their capacity to modulate GU tract colonisation, 288 
an essential step in the pathogenesis of both microorganisms.  289 
Using VEC line VK2/E6E7 as a model system, this study provides evidence that a 290 
reciprocal, synergistic relationship exists between GBS and C. albicans that may serve 291 
to promote their co-colonisation of the vaginal mucosa. Specifically, when incubated 292 
together, numbers of both microbes associated with the epithelial monolayers were 293 
found to be significantly higher than the numbers recovered from equivalent 294 
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monospecies samples. Confocal microscopy revealed extensive hyphal ‘mats’ of 295 
candidal cells overlaying the epithelial monolayers to which GBS cells were attached. 296 
This infers that direct physical contact (i.e. coadhesion) between GBS and C. albicans is 297 
a key mechanism that contributes to their synergistic interplay. Thus GBS may bind 298 
directly to epithelium or to adherent C. albicans cells, and vice versa. 299 
To identify the mechanistic basis of coadhesion between GBS and C. albicans, 300 
studies focused on the hypha-specific adhesins of C. albicans and specifically adhesin 301 
Als3, since a distinct tropism for candidal hyphae was observed for both GBS strains 302 
tested. Use of Als3 knockout and complemented strains of C. albicans confirmed that 303 
recognition of this glycoprotein by GBS is required for effective coaggregation of these 304 
two microbes under planktonic conditions, and for co-association with vaginal 305 
epithelium. This correlates well with the interactions of C. albicans and streptococci 306 
within the oral cavity reported to date (32, 34) and thus may infer that Als3 recognition 307 
represents a common mechanism for C. albicans engagement by the Streptococcus 308 
genus. The addition of GBS to the list of microbes that utilise Als3 as a receptor, 309 
alongside other streptococci, Staph. aureus and Rothia dentocariosa (32, 37, 43), also 310 
adds support to the notion that Als3 plays a major role in the capacity for C. albicans to 311 
mediate a diverse range of polymicrobial interactions. 312 
In addressing the GBS side of this synergistic partnership, this study provides 313 
evidence for the role of GBS AgI/II family (Bsp) adhesins in this process. Previous work 314 
has implicated BspA in facilitating coaggregation of GBS strain NEM316 with C. 315 
albicans under planktonic conditions (12). These data are supported here and 316 
developed to include adhesin BspC, implying that these capabilities may represent 317 
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functions that are shared across the Bsp adhesin family. Moreover, loss of BspC 318 
impaired GBS co-association with C. albicans, while expression of BspC by L. lactis 319 
enabled C. albicans to promote association of this surrogate host with VEC monolayers. 320 
This extends our current understanding of the properties of the adhesin family and 321 
implies that Bsp adhesins are determinants of GBS that facilitate co-association with C. 322 
albicans on vaginal epithelium. Moreover, coggregation between surrogate hosts 323 
expressing Als3 and Bsp adhesins adds support to the hypothesis that direct binding 324 
between Bsp polypeptides of GBS and Als3 of C. albicans is a mechanism that 325 
underpins, at least in part, the synergy in epithelial cell interactions between these two 326 
microbes. Interestingly, while deletion of bspC did not ablate co-association between 327 
GBS and C. albicans, deletion of both als3 alleles effectively prevented the interaction. 328 
This indicates a role for additional GBS determinants in mediating the interkingdom 329 
relationship, and implies that these determinants may also target candidal receptor 330 
Als3. This supports the evidence that Als3 has capacity to bind multiple, diverse ligands 331 
(44). 332 
Based on primary sequence, the AgI/II family polypeptides of GBS can be divided 333 
into four homologues: BspA and B, which share 90% sequence identity, and BspC and 334 
D, which share 99% sequence identity (12). The highest level of variation between 335 
BspA/B and BspC/D is seen within the N-terminal alanine-rich and proline-rich domains. 336 
By contrast, the V domain shares 96-100% sequence identity across all four Bsp 337 
homologues (12). The V domain has been identified as the functional region of a 338 
number of AgI/II family polypeptides (45-47), including BspA, where it was shown to 339 
promote binding of GBS NEM316 to scavenger receptor agglutinin glycoprotein-340 340 
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(12). If the V domain is also responsible for GBS co-association with C. albicans, the 341 
high level of sequence similarity may explain why both BspA and BspC display 342 
comparable functional properties. Delineating the precise domains within Bsp that are 343 
required for engagement with candidal Als3 will be the focus of future studies.  344 
It is clear that direct physical contact between C. albicans and GBS plays a 345 
significant role in their co-association with VECs. We also considered the possibility that 346 
intermicrobial signals played a role in the processes described. However, no evidence 347 
was found for diffusible molecules released by either C. albicans or GBS having the 348 
capacity to significantly modulate microbial interactions with vaginal epithelium. 349 
Nonetheless, provision of additional intermicrobial binding sites may not be the only 350 
mechanism involved in the synergy with VECs. For example, in dual-species images 351 
there were patches of epithelium that were heavily colonised by GBS while seemingly 352 
devoid of C. albicans (Fig. 3). Fixation of VECs did not inhibit co-association between 353 
GBS and C. albicans, implying that these effects are not dependent upon modulation of 354 
epithelial cell biology (e.g. receptor availability). Nonetheless, it remains possible that 355 
GBS engagement with C. albicans alters the GBS receptor profile such that these 356 
bacteria are subsequently more permissive to interactions with VECs. The large impact 357 
of als3 gene deletion on the GBS-C. albicans-VEC co-association raises the prospect 358 
that Als3 may mediate such effects. Future studies will explore these possible 359 
explanations. 360 
To conclude, this study identifies for the first time a synergistic interplay between 361 
GBS and C. albicans that enhances the capacity of both microorganisms to associate 362 
with vaginal epithelial cells. Molecular determinants critical to this co-association 363 
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mechanism are identified as Bsp adhesins of GBS, and Als3 of C. albicans. GU tract 364 
colonisation is an essential first step in the pathogenesis of diseases such as vaginal 365 
thrush, and is a significant risk factor for GBS neonatal disease due to vertical 366 
transmission. Co-association between GBS and C. albicans may therefore have 367 
important implications for disease risk by both of these opportunistic pathogens. This 368 
co-association also raises the intriguing possibility of utilising a convergent immunity 369 
approach to develop novel intervention strategies, as has been explored for C. albicans 370 
and Staph. aureus (48). There is currently no vaccine against GBS disease. 371 
Furthermore, while use of intrapartum antibiotic prophylaxis (IAP) has been successful 372 
in decreasing the incidence of early-onset neonatal GBS disease in some countries, the 373 
logisitics of IAP make it an unrealistic control strategy for rural and developing countries, 374 
and IAP has had no impact on the rate of late-onset GBS infection (49, 50). The data 375 
presented here imply that better control of vaginal colonisation by C. albicans may 376 
restrict or reduce GBS colonisation, which in turn would reduce the risk of GBS 377 
transmission. Hence vaccines against C. albicans, such as the promising rAls3 vaccine 378 
that has completed phase 1 clinical trials (51), could concomitantly help to reduce the 379 
burden of neonatal GBS disease. 380 
 381 
MATERIALS AND METHODS 382 
Microbial strains and culture conditions. The microbial strains used in this 383 
study are listed in Table 1. GBS strains were cultured in Todd-Hewitt broth with 0.5% 384 
Yeast Extract (THY) or on THY agar plates at 37 °C, 5% CO2. Lactococcus lactis was 385 
cultured in GM17 broth (M17 broth supplemented with 0.5% glucose) or on GM17 agar 386 
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plates at 30 °C in a candle jar. Escherichia coli was cultured aerobically in Luria Bertani 387 
(LB) broth or on LB agar plates at 37 °C. Media were supplemented with 5 μg/ml 388 
erythromycin, or with 50 μg/ml (E. coli) or 5 μg/ml (GBS) chloramphenicol as 389 
appropriate. Heterologous protein expression in L. lactis was induced from nisin-390 
inducible plasmids by the addition of 10 ng/ml nisin. Cells from GBS and L. lactis broth 391 
cultures were harvested by centrifugation at 5000 g for 7 min.  392 
C. albicans was cultured in YPD medium (1% Yeast Extract, 2% Mycological 393 
peptone, 2% glucose) at 37 °C with shaking (220 rpm), or maintained on Sabouraud 394 
dextrose (SAB) agar plates incubated aerobically at 37 °C. C. albicans cells were 395 
harvested from broth cultures by centrifugation at 5000 g for 5 min. S. cerevisiae was 396 
cultured in complete supplement medium (CSM) without uracil (ForMedium) 397 
supplemented with 0.67% yeast nitrogen base (YNB; Difco) and 2% glucose at 30 oC 398 
with shaking. 399 
Generation of GBS knockout and L. lactis surrogate expression strains. A 400 
ΔbspC mutant was generated in GBS strain 515 by in-frame allelic replacement with a 401 
chloramphenicol resistance cassette by homologous recombination, using a method 402 
previously described (52). Briefly, a knockout construct was generated by amplifying 403 
flanking regions directly upstream and downstream of the bspC gene from GBS strain 404 
515 genomic DNA using primer pairs bspC.F1/bspC.R1 and bspC.F2/bspC.R2 405 
respectively (Table 2). A cat cassette was amplified from chloramphenicol-resistant 406 
plasmid pR326 using primers cat.F and cat.R (Table 2). Upstream and downstream 407 
bspC and cat amplicons were then combined by stitch PCR using primers bspC.F1 and 408 
bspC.R2. The resultant amplicon was cloned into vector pHY304 (53) via XbaI and 409 
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BamHI sites, and propagated in E. coli StellarTM (Clontech) prior to isolation and 410 
electroporation into GBS 515. 411 
A L. lactis strain expressing BspA had been generated previously (12), and a 412 
similar methodology was employed here to generate a L. lactis strain expressing BspC. 413 
In brief, the bspC gene was amplified from GBS strain 515 genomic DNA using primers 414 
pMSP.bspC.F and pMSP.bspC.R (Table 2). The resultant amplicon was then cloned 415 
into nisin-inducible expression vector pMSP7517 (54) via NcoI and XhoI sites, 416 
generating plasmid pMSP.bspC. This construct was transformed directly into 417 
electrocompetent L. lactis NZ9800, as described previously (12). Transformants were 418 
confirmed by plasmid isolation and PCR, while expression of BspC in L. lactis was 419 
verified by dot immunoblot. 420 
Tissue culture. Experiments were conducted using VK2/E6E7 cells (ATCC CRL-421 
2616), an immortalised human VEC line with a similar protein profile to the natural 422 
tissue (55, 56). VECs were cultured in K-SFM (Gibco®) supplemented with 0.4 mM 423 
CaCl2, 0.05 mg/ml Bovine Pituitary Extract and 0.1 ng/ml Epidermal Growth Factor. 424 
Upon reaching 70-80% confluence, cells were disassociated using TrypLE express 425 
trypsin replacement reagent (Gibco®) before being harvested and resuspended in K-426 
SFM. Appropriate volumes of cells were seeded to fresh flasks or to assay plates, as 427 
required.  428 
Visualisation of dual-species planktonic interactions. Cells from 16 h cultures 429 
of C. albicans were harvested, washed in YNBPT (1x Yeast Nitrogen Base, 20 mM 430 
Na2HPO4, 0.02% tryptone, adjusted to pH 7) and suspended to OD600 1.0 (equivalent to 431 
106 cells/ml) in YNBPT. This suspension was diluted 1:10 into YNBPTG (YNBPT 432 
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supplemented with 0.4% glucose) and incubated at 37 °C, 220 rpm for 2 h (2 ml final 433 
volume). These growth conditions have previously been shown to induce candidal 434 
hyphae formation (57). 435 
GBS cells were harvested from 16 h cultures, washed in YNBPT, and then 436 
suspended in 1.5 mM fluorescein isothiocyanate (FITC) dissolved in carbonate buffer 437 
(100 mM NaCl, 50 mM Na2CO3), and incubated for 30 min with gentle agitation. GBS 438 
cells were harvested, washed three times in carbonate buffer and the pellet suspended 439 
and adjusted to OD600 0.5 (equivalent to 5x10
7 cells/ml) in YNBPTG. GBS suspension 440 
(1 ml) was added to that of C. albicans and incubated at 37 °C for a further 1 h with 441 
shaking. Calcofluor White (0.00001% in dH2O) was added before visualisation of 10 μl 442 
samples by fluorescence microscopy.  443 
For quantification assays, approximately 40 images were taken of randomly 444 
selected hyphae from each experimental group. Interactions were scored into one of 445 
four groups, similar to the method reported previously (32): 0 interacting bacteria per 446 
hypha, 1-5 bacteria, 6-20 bacteria, and more than 20 bacteria per hypha. 447 
In a variation of this assay, Saccharomyces cerevisiae cells were harvested from a 448 
16 h overnight broth culture in CSM broth, washed once in YNBPT (5 ml), and stained 449 
in 1.5 mM FITC for 30 min with gentle agitation. S. cerevisiae were harvested and 450 
washed three times in carbonate buffer. The pellet was suspended and adjusted to 451 
OD600 1.0 (equivalent to 10
6 cells/ml) in YNBPTG, before 1:5 dilution into YNBPTG (final 452 
volume 2 ml). This suspension was incubated at 30 °C, 220 rpm for 3 h. L. lactis strains 453 
were harvested from a 16 h overnight broth culture and washed once in YNBPT before 454 
suspension in 2 mL TRITC (0.1 mg/ml in carbonate buffer) and incubated for 30 min 455 
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with gentle agitation. L. lactis cells were harvested, washed three times in carbonate 456 
buffer and adjusted to OD600 0.5 in YNBPTG (equivalent to 5x10
7 cells/ml). Adjusted L. 457 
lactis suspension (1 ml) was added to S. cerevisiae and incubated for a further 1 h at 30 458 
°C, 220 rpm, before visualisation of 10 μl samples by fluorescence microscopy. 459 
Microbial growth in dual-species broth cultures. Cells from overnight (16 h) C. 460 
albicans suspension culture were harvested and washed once in phosphate-buffered 461 
saline (PBS). The pellet was suspended and adjusted to OD600 1.0 in K-SFM before a 462 
1:10 dilution into K-SFM (2 ml final volume) and incubation at 37 °C, 220 rpm for 2 h. 463 
Cells from overnight GBS broth cultures were harvested, washed once in PBS, and 464 
suspended in K-SFM at OD600 0.5. GBS  suspension (1 ml) was added to C. albicans 465 
suspension and the mixture incubated at 37 °C for a further 1 h. Planktonic suspensions 466 
were vortex mixed for 15 s before serial 10-fold dilutions into THY broth. Numbers of 467 
microorganisms were detected by viable count (CFU) on either THY agar plates (GBS) 468 
supplemented with 50 μg/ml nystatin to inhibit C. albicans growth, or SAB agar plates 469 
(C. albicans) supplemented with 5 μg/ml erythromycin to inhibit GBS growth. 470 
Epithelial association assay. Epithelial association assays were conducted as 471 
described by (5) with a few modifications. VECs were seeded into a 24-well plate at 472 
2x105 cells/well and incubated until confluent at 37 °C, 5% CO2 (48-72 h). C. albicans 473 
cells were diluted in K-SFM to obtain approximately 5x105 cells/ml, while GBS or L. 474 
lactis cells were diluted into K-SFM to obtain approximately 5x105 cells/ml.  475 
Wells containing VEC monolayers were washed once with PBS and 476 
approximately 5x105 bacteria or C. albicans (1 ml; MOI 2.5) were then added to each 477 
well. Bacterial suspensions were incubated at 37 °C, 5% CO2 for 1 h, while C. albicans 478 
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suspensions were incubated for 2 h. For dual species assays, C. albicans suspensions 479 
were incubated for 1 h before the medium was replaced by GBS or L. lactis and 480 
incubated for a further 1 h. For all assays, wells were then washed three times with PBS 481 
before incubation for 15 min with TrypLE™, followed by two ice cold water incubations, 482 
lasting 20 min each, to lyse the VECs. Lysates were serially diluted onto THY (GBS), 483 
GM17 (L. lactis) or SAB (C. albicans) agar plates and viable counts determined, as 484 
described above. It was confirmed both visually and by monitoring levels of lactate 485 
dehydrogenase (LDH) released into the culture supernatants that epithelial monolayers 486 
remained intact and viable over the time periods for mono- or dual-species association 487 
assays. 488 
In a variation of this assay, VEC monolayers were fixed in 2% paraformaldehyde 489 
overnight prior to incubation with cell suspensions of C. albicans and/or GBS. 490 
Alternatively, GBS suspensions were prepared as described above and preincubated at 491 
room temperature with 10 µg/ml rabbit preimmune or anti-Bsp sera (Eurogentec) for 30 492 
min, prior to incubation at 37 oC for 1 h with VEC monolayers.  493 
Spent media studies. VECs were seeded in a 24-well plate and grown to 494 
confluence. C. albicans was prepared as described above, and incubated with the 495 
VECs, or grown planktonically in K-SFM medium, for 1 h. C. albicans media were then 496 
collected and sterilised by filtration through a 0.2 μm filter. GBS suspensions, prepared 497 
as above, were adjusted to OD600 1.0 in K-SFM, before a 1:200 dilution into either fresh 498 
K-SFM, K-SFM from C. albicans planktonic growth, or K-SFM from C. albicans growth 499 
on VK2/E6E7 monolayers. Aliquots (1 ml) were added to VEC monolayers and 500 
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incubated for 1 h. VECs were disassociated and lysed as above, with CFU of GBS 501 
determined by serial dilution and viable count on THY agar plates. 502 
Transwell studies. VECs were seeded in a 24-well plate and grown to 503 
confluence. C. albicans cells were prepared as above, and incubated with VEC 504 
monolayers for 1 h before the medium was replaced with 1 ml K-SFM. Transwell inserts 505 
with high density pores of 0.4 µm (Sarstedt) were placed into wells. GBS suspensions in 506 
K-SFM (OD600 1.0) were diluted 1:100 into K-SFM. Aliquots (0.5 ml) were added to the 507 
transwell inserts and the plates incubated for a further 1 h. The inserts were removed, 508 
remaining VECs were disassociated and lysed as described above, and C. albicans 509 
CFU determined by serial dilution and viable count on SAB agar plates. 510 
Confocal microscopy. For visualisation by confocal microscopy, VEC 511 
monolayers were grown on 19 mm glass cover slips in a 12-well plate until confluent. 512 
The epithelial association assay was then carried out as described above, except that 513 
the time was extended by 4 h. Calcofluor White (1 μl) was added to stain the chitin in 514 
the C. albicans cell wall, and the cover slips then fixed in 2% paraformaldehyde. Triton 515 
X-100 (0.3%) was used to permeabilise the epithelial cells before blocking in 2% BSA. 516 
Bacteria were stained with a mouse anti-GBS antibody (1.B.501, Santa Cruz 517 
Biotechnology) followed by a goat anti-mouse Alexafluor-488 conjugated antibody 518 
(Fisher), both of which were used at a dilution of 1:200. The F-actin of the epithelial cells 519 
was stained with phalloidin-TRITC (Sigma). Cover slips were then mounted onto glass 520 
slides using Vectashield (Vector Labs), and imaged on a Leica SP5-AOBS confocal 521 
laser scanning microscope (CSLM) attached to a Leica DM I6000 inverted 522 
epifluorescence microscope. Images were processed using Volocity® software and 523 
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Imaris® v7.5 software (Bitplane AG, Zurich, Switzerland) was used to calculate 524 
biovolumes (µm3). 525 
Statistical analyses. All assays were performed in triplicate unless otherwise 526 
stated. Data were analysed using unpaired Student’s t tests with Bonferroni correction, 527 
as appropriate. 528 
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 716 
FIGURE LEGENDS 717 
FIG 1 Fluorescence micrographs of planktonic interactions between C. albicans and 718 
GBS. C. albicans SC5314 was grown in YNBPTG for 2 h at 37 °C, 220 rpm before 719 
addition of (A) GBS strain NEM316 or (B) GBS strain 515, and incubation for a further 1 720 
h. GBS was labelled with FITC (green), while C. albicans was labelled with Calcofluor 721 
White (blue). Scale bars, 20 μm. 722 
 723 
FIG 2 Effects of C. albicans SC5314 on association of GBS with VECs. VEC 724 
monolayers were incubated with GBS suspensions (MOI 2.5) for 1 h (open bars) or with 725 
C. albicans (MOI 2.5) for 1 h followed by GBS for a further 1 h (black bars). Monolayers 726 
were then lysed and numbers of associated GBS enumerated by serial dilution onto 727 
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THY agar supplemented with 50 μg/mL nystatin. * indicates P<0.05 compared to 728 
monospecies controls, as determined by unpaired Student’s t-test; n = 4. 729 
 730 
FIG 3 Representative confocal micrographs of C. albicans-GBS association with VECs. 731 
VEC monolayers were incubated with GBS alone for 5 h (columns 1 and 2) or with C. 732 
albicans for 1 h followed by GBS for a further 5 h (columns 3 and 4). Cells were then 733 
fixed, stained and mounted onto glass slides. GBS was labelled using Alexafluor-488-734 
conjugated antibody (green), while C. albicans was labelled with Calcofluor White 735 
(blue), and VECs were labelled with phalloidin-TRITC (red). GBS strains NEM316 (top 736 
panels) and 515 (bottom panels) were tested. Columns 2 and 4 are duplicates of 737 
columns 1 and 3, respectively, in which the red filter (i.e. the VECs) has been removed 738 
(VK2/E6E7 off). Scale bars, 100 μm. White arrows indicate areas where GBS binds C. 739 
albicans hyphae, while red arrows indicate areas where GBS is found in the absence of 740 
C. albicans. 741 
 742 
FIG 4 Effects of C. albicans on association of GBS with VECs following 5 h incubation. 743 
(A) Quantification of GBS from confocal micrographs illustrated in Fig. 3. Images were 744 
processed using Volocity® software and Imaris® software was used to calculate GBS 745 
biovolumes (µm3). (B) Quantification of GBS by viable count. VEC monolayers were 746 
incubated with GBS suspensions for 5 h (open bars) or with C. albicans for 1 h followed 747 
by GBS for a further 5 h (black bars). Monolayers were then lysed and numbers of 748 
associated GBS enumerated by serial dilution onto THY agar supplemented with 50 749 
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μg/mL nystatin. ** indicates P<0.01 compared to monospecies controls, as determined 750 
by unpaired Student’s t-test; n = 4. 751 
 752 
FIG 5 Effects of GBS on association of C. albicans SC5314 (WT) with VECs. VEC 753 
monolayers were incubated with C. albicans cells for 1 h to allow production of hyphae. 754 
GBS suspensions were then added for a further 1 h, before monolayers were lysed. 755 
Numbers of associated C. albicans were enumerated by serial dilution onto SAB agar 756 
supplemented with 5 μg/mL erythromycin. * indicates P<0.05 compared to the 757 
monospecies control, as determined by unpaired Student’s t-test with Bonferroni 758 
correction; n = 3. 759 
 760 
FIG 6 Growth of C. albicans or GBS in mono- or dual-species suspension culture. K-761 
SFM broth cultures were inoculated with C. albicans SC5314 (WT) at 37 °C, 220 rpm for 762 
1 h before addition of GBS and incubation for a further 1 h (black bars). Alternatively 763 
broth cultures were inoculated with C. albicans or GBS alone and incubated for 2 h or 1 764 
h respectively (open bars). C. albicans CFU/mL were then determined by viable count 765 
onto SAB agar supplemented with 5 μg/mL erythromycin (A), while GBS CFU/mL were 766 
determined by viable count onto THY agar supplemented with 50 μg/mL nystatin (B). 767 
‘NS’ indicates P>0.05 compared to the monospecies control, as determined by unpaired 768 
Student’s t-test; n = 3. 769 
 770 
FIG 7 Role of contact-independent mechanisms or fixation in modulating interactions of 771 
C. albicans or GBS with VECs. (A) C. albicans SC5314 (WT) was grown on VEC 772 
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monolayers, or planktonically in K-SFM medium, for 1 h before spent media were 773 
collected and filter sterilised. GBS cells were incubated in these spent media on VECs 774 
for 1 h, before monolayers were lysed and numbers of associated GBS enumerated by 775 
serial dilution onto THY agar. ‘NS’ indicates P>0.05 compared to the blank K-SFM 776 
control, as determined by unpaired Student’s t-test; n = 3. (B) C. albicans was grown on 777 
VEC monolayers for 1 h, before GBS suspensions or K-SFM alone were placed into 778 
transwell baskets suspended above. After a further 1 h incubation, C. albicans was 779 
enumerated by serial dilution onto SAB agar. (C,D) VEC monolayers were fixed with 2% 780 
paraformaldehyde and then incubated with GBS suspensions (MOI 2.5) for 1 h (open 781 
bars) or with C. albicans (MOI 2.5) for 1 h followed by GBS for a further 1 h (black bars). 782 
Monolayers were then lysed and GBS CFU/mL determined by viable count onto THY 783 
agar supplemented with 50 μg/mL nystatin (C), while C. albicans CFU/mL were 784 
determined by viable count onto SAB agar supplemented with 5 μg/mL erythromycin 785 
(D). ‘NS’ indicates P>0.05, ** indicates P<0.01 compared to monospecies controls, as 786 
determined by unpaired Student’s t-test with Bonferroni correction; n = 4 (A,B) or 3 787 
(C,D). 788 
  789 
FIG 8 Effects of C. albicans or Bsp antisera on the association of GBS wild type or 790 
isogenic mutant strains with VECs. (A) VEC monolayers were incubated with GBS wild 791 
type (WT) 515 or mutant bspC cell suspensions (MOI 2.5) for 1 h (open bars), or with 792 
C. albicans SC5314 (MOI 2.5) for 1 h followed by addition of strain 515 suspensions for 793 
a further 1 h (black bars). Monolayers were then lysed and numbers of associated GBS 794 
were enumerated by serial dilution onto THY agar supplemented with 50 μg/mL 795 
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nystatin. ** indicates significance relative to monospecies controls; Ω indicates 796 
significance relative to wild type monospecies control; § indicates significance relative to 797 
wild type in the presence of C. albicans. (B) GBS cell suspensions were preincubated 798 
with preimmune (open bars) or anti-Bsp (black bars) sera, before incubation with VEC 799 
monolayers (MOI 2.5) for 1 h and enumeration from cell lysates by viable count. ** 800 
indicates significance relative to preimmune controls. Significance indicates P<0.01, as 801 
determined by unpaired Student’s t-test with Bonferroni correction; n = 3. 802 
 803 
FIG 9 Effects of C. albicans on the association of L. lactis Bsp surrogate expression 804 
strains with VECs. VEC monolayers were incubated with suspensions of L. lactis pMSP 805 
vector control, pMSP.BspA or pMSP.BspC (MOI 2.5) for 1 h (open bars), or with C. 806 
albicans SC5314 (MOI 2.5) for 1 h followed by addition of L. lactis suspensions for a 807 
further 1 h (black bars). Monolayers were then lysed and numbers of associated L. 808 
lactis were enumerated by serial dilution onto GM17 agar supplemented with 50 μg/mL 809 
nystatin. ** indicates significance relative to monospecies controls; Ω indicates 810 
significance relative to pMSP empty vector control; § indicates significance relative to 811 
pMSP empty vector control in the presence of C. albicans. Significance indicates 812 
P<0.01, as determined by unpaired Student’s t-test with Bonferroni correction; n = 4. 813 
 814 
FIG 10 Role of Als3 in planktonic interactions between C. albicans and GBS. (A) 815 
Fluorescence micrographs of planktonic interactions between C. albicans Δals3 (left 816 
panel) or Δals3+als3 complemented strain (right panel) with GBS strains NEM316 (top 817 
panels) or 515 (bottom panels). C. albicans was grown in YNBPTG for 2 h at 37 °C, 220 818 
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rpm before addition of GBS and incubation for a further 1 h. GBS was labelled with 819 
FITC (green), while C. albicans was labelled with Calcofluor White (blue). Scale bars, 820 
20 μm. Note, interactions of GBS strains with C. albicans SC5314 wild type are shown 821 
in Fig. 1. (B) Semi-quantitation of numbers of C. albicans hyphae with 0, 1-5, 6-20 or 822 
>20 interacting GBS, based on approximately 40 randomly selected images from each 823 
experimental group. * indicates P<0.05; ‘NS’ indicates P>0.05, as determined by linear 824 
regression analysis of datasets; n = 4. 825 
 826 
FIG 11 Role of Als3 in synergistic effects of C. albicans on association of GBS with 827 
VECs. VEC monolayers were incubated with GBS suspensions for 1 h (open bars) or 828 
with C. albicans SC5314 wild type (WT) (black bars), Δals3 (grey bars) or Δals3+als3 829 
(hashed bars) for 1 h, followed by GBS for a further 1 h. Monolayers were lysed and 830 
then numbers of associated GBS were enumerated by serial dilution onto THY agar 831 
supplemented with 50 μg/mL nystatin. ** indicates P<0.01; ‘NS’ indicates P>0.05, as 832 
determined by unpaired Student’s t-test with Bonferroni correction; n = 4. 833 
  834 
FIG 12 Role of Als3 in synergistic effects of GBS on association of C. albicans with 835 
VECs. VEC monolayers were incubated with C. albicans SC5314 wild type (WT) (open 836 
bars), Δals3 (black bars) or Δals3+als3 (striped bars) for 1 h followed by GBS for a 837 
further 1 h. Monolayers were lysed and numbers of associated C. albicans were 838 
enumerated by serial dilution onto SAB agar supplemented with 5 μg/mL erythromycin. 839 
** indicates P<0.01; ‘NS’ indicates P>0.05, as determined by unpaired Student’s t-test 840 




FIG 13 Fluorescence micrographs of planktonic interactions between S. cerevisiae Als3 843 
and L. lactis Bsp surrogate expression strains. S. cerevisiae (Als3+) was grown in 844 
YNBPTG for 3 h at 30 °C, 220 rpm before addition of (A) L. lactis (pMSP control), (B) L. 845 
lactis (pMSP.BspA) or (C) L. lactis (pMSP.BspC) and incubation for a further 1 h. L. 846 
lactis was labelled with TRITC (red), while S. cerevisiae was labelled with FITC (green). 847 
Scale bars, 20 μm. 848 
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TABLE 1 Microbial strains used in this study 849 
Strain or plasmid Unique ID # Relevant genotype Reference or source 
C. albicans    
SC5314 UB1843 Wild type Neil Gow, Univ 
Aberdeen 
UB1941 Δals3 (39) 
UB1940 Δals3+pUL.als3 (39) 
S. cerevisiae    
BY4742 UB2156 pBC542-ALS3sm (40) 
S. agalactiae    
NEM316 
 
UB1931 Wild type Shaynoor Dramsi, 
Institut Pasteur 
515 UB2410 Wild type Victor Nizet, Univ 
California San Diego 
515 UB2873 ΔbspC This study 
L. lactis    
NZ9800 UB2635 pMSP (12) 
UB2658 pMSP.bspA (12) 
UB2659 pMSP.bspC This study 
    
Plasmids    





containing E. faecalis 
prgB under control of 
nisA promoter; 
erythromycinR 
pMSP.bspC  pMSP7517-derived 
containing bspC from 
GBS 515 in place of 
prgB 
 




  853 
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TABLE 2 Primers used in this study 854 










a Restriction endonuclease sites are underlined. 856 
 857 













